PTEN tumor suppressor gene failure in ras Ha -activated skin carcinogenesis was investigated by mating exon 5 floxed-PTEN (#5PTEN) mice to HK1.ras mice that expressed a RU486-inducible cre recombinase (K14.creP). PTEN inactivation in K14.cre/PTEN flx/flx keratinocytes resulted in epidermal hyperplasia/hyperkeratosis and novel 12-O-tetradecanoylphorbol-13-acetate (TPA)-promoted papillomas, whereas HK1.ras/K14.cre/PTEN flx/flx cohorts displayed a rapid onset of papillomatogenesis due to a synergism of increased AKT activity and extracellular signal-regulated kinase (ERK) elevation. High 5-bromo-4-deoxyuridine labeling in #5PTEN papillomas showed that a second promotion mechanism centered on failures in cell cycle control. Elevated cyclin D1 was associated with both HK1.ras/ERK-and #5PTEN-mediated AKT signaling, whereas cyclin E2 overexpression seemed dependent on PTEN loss. Spontaneous HK1.ras/ #5PTEN malignant conversion was rare, whereas TPA promotion resulted in conversion with high frequency. On comparison with all previous HK1.ras carcinomas, such TPAinduced carcinomas expressed atypical retention of keratin K1 and lack of K13, a unique marker profile exhibited by TPAinduced K14.cre/PTEN flx/flx papillomas that also lacked endogenous c-ras Ha activation. Moreover, in all PTEN-null tumors, levels of ras Ha -associated total ERK protein became reduced, whereas phosphorylated ERK and cyclin D1 were lowered in late-stage papillomas returning to elevated levels, alongside increased cyclin E2 expression, in TPA-derived carcinomas. Thus, during early papillomatogenesis, PTEN loss promotes ras
Introduction
The roles of PTEN tumor suppressor gene signaling have been under intense scrutiny given that loss of function via mutation, genetic silencing, and chromosomal deletion have been identified in human cancers at frequencies that rival p53 (1) (2) (3) . Germ line PTEN mutations occur in hereditary cancer-associated diseases, such as Cowden syndrome (4) , which exhibits cutaneous lesions, suggesting that PTEN may play an important role in keratinocyte differentiation (5) . PTEN functions as a lipid and protein phosphatase that targets phosphatidylinositol (3, 4, 5) triphosphate (PIP3; refs. 6, 7), the product of phosphatidylinositol 3-kinase, to negatively regulate growth factor signaling, including ras (8) . This serves to antagonize PIP3-mediated activation of PKB/AKT, a serinethreonine kinase that phosphorylates key intermediate signaling molecules leading to increased proliferation and cell survival (6, 7) . Hence, loss of PTEN function results in accumulation of activated AKT that plays a key role in PTEN-mediated tumorigenesis via anti-apoptosis mechanisms (1) (2) (3) 9) , overexpression of cyclin D (10) , and interactions with MDM2 that lead to increased p53 degradation (1-3, 9, 11) . Alternate mechanisms of PTEN-mediated tumorigenesis, possibly independent of AKT (12, 13) , show that PTEN directly associates with p53 increasing stability, protein levels, and transcriptional activity (14) . Similarly, PTEN regulates cell cycle arrest via protein phosphatase-dependent interaction with cyclin D and phospholipase-dependent p27 kip mechanisms (15) , consistent with inhibition of S phase via recruitment of p27 kip into cyclin E complexes following adenovirus-mediated delivery of PTEN (16) and cooperation between PTEN loss and p27 kip in prostate cancer (17) . The oncogenic potential of PTEN is further highlighted by roles in integrin signaling and an ability to dephosphorylate focal adhesion kinase that reduce cell adhesion and enhance migration (12, 18) .
Transgenic studies showed that although knockout of PTEN is embryonically lethal, heterozygous mice develop several tumor types (19, 20) . Moreover, in conditional mammary or prostate models, PTEN loss also resulted in developmental defects, highlighting the importance of PTEN to normal differentiation (21, 22) . In conditional epidermal knockouts, 7,12-dimethylbenz (a)anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA) chemical carcinogenesis elicited tumors that rapidly progressed to carcinoma (23) via mechanisms centered on failed apoptosis and increased mitogen-activated protein kinase (MAPK) activity, consistent with AKT activation in classic two-stage chemical carcinogenesis (10) . However, DMBA/TPA chemical carcinogenesis using heterozygous PTEN knockout mice (24) found that whereas papillomas exhibited ras Ha activation (25) , squamous cell carcinomas failed to exhibit any ras mutations, suggesting that mutually exclusive pathways existed between ras Ha -mediated and PTENmediated carcinogenesis (24) .
Thus, to investigate PTEN loss in ras Ha -mediated skin carcinogenesis, an RU486-inducible keratin K14-driven cre (26) was used to ablate lox-P flanked PTEN exon 5 functions (D5PTEN; refs. 14, 21) at localized epidermal sites, including stem cells (26) , the presumed targets for carcinogens (27) . Previously, using a human keratin K1 promoter, ras
Ha expression in transit amplifying keratinocytes (HK1.ras) resulted in benign papillomas (28) , whereas mating experiments to model ras/fos or ras/p53 mechanisms (29) (30) (31) resulted in papillomas but without conversion that required additional events (32, 33) . In this study, ras
Ha and D5PTEN cooperated at the onset of papillomatogenesis but progression via ras Ha -associated marker mechanisms gave cells with only limited malignant potential, whereas TPA promotion selects a population of D5PTEN-associated cells that converted to malignancy with high frequency.
Materials and Methods
RU486 treatment of transgenic mice. Characterization of HK1.ras (28, 31) , inducible K14.creP regulator (26) , and PTEN flx/flx lines (14, 21) have been described previously and breeding strategies maintained HK1.ras and K14.creP transgenes as heterozygotes with wild-type (PTEN wt/wt ), heterozygous (PTEN wt/flx ), or homozygous (PTEN flx/flx ) floxed D5PTEN alleles, respectively. To achieve epidermal PTEN ablation, cre recombinase was activated in dorsal skin or ears via topical treatment with 2. Genotype analysis and transgene expression. Skin and tumor biopsies were frozen in liquid nitrogen before DNA or total RNA isolation using the Rneasy Midi kit (Qiagen, Sussex, United Kingdom). HK1.ras mice were genotyped as described previously (28) and expression was confirmed via reverse transcription-PCR (RT-PCR). cDNA was generated using SuperScript II reverse transcriptase (Invitrogen, Paisley, United Kingdom) and amplified using HK1.ras primers that spanned the HK1 intron to rule out DNA contamination ( forward: 5-GGATCCGATGACAGAATACAAGC-3; reverse 5-ATCGATCAGGACAGCACACTTGCA-3) under conditions described previously (30) . K14.creP mice were identified by a 410 bp band using primer pairs forward 5V -TCATTTGGAACGCCCACT-3 and reverse 5V -GATCCCGAA-TAACTACCTGTTTTG-3V, and reaction conditions of 95jC for 5 minutes, 35 cycles of 45-second denaturation at 95jC, 1-minute annealing at 60.7jC, 1-minute extension at 72jC, and final 15-minute extension at 72jC. PTEN flx/flx mice were identified by a floxed allele-specific band at f1,100 bp and wild-type allele at f900 bp (14, 21) using primer pairs P1 forward 5V -ACTCAAGGCAGGGATGAGC-3V and P2 (exon 5-specific) reverse 5V -GTC-ATCTTCACTTAGCCATTGG-3V , and reaction conditions of 94jC (2 minutes), 35 cycles of 30-second denaturation at 94jC, 1-minute annealing at 64jC, 1.5-minute extension at 72jC, and 10-minute extension at 72jC. PTEN exon 5 ablation was detected by a nested PCR using identical reaction conditions and a second reverse primer P3, 5V-GCTTGATATC-GAATTCCTGCAGC-3V, sited 3V distal to the downstream lox P site (21), which gave an additional 400 bp P1 to P3 band (D5PTEN).
Histology, immunofluorescence, and 5-bromo-4-deoxyuridine labeling analysis. Skin and tumor biopsies were fixed in 10% formalin overnight at 4jC, stored in 70% ethanol, and stained with H&E. Biopsy samples were also frozen in optimum cutting temperature solution and stored at À70jC.
For immunofluorescence, frozen sections (5-7 Am) were incubated overnight with rabbit anti-K13 (a gift from D. Roop, Cell Biology, Baylor College of Medicine, Houston, TX), anti-K1, antiloricrin, antifilaggrin (diluted 1:500; Covance/Cambridge Bioscience, Cambridge, United Kingdom), or guinea pig anti-K14 antibodies (dilution 1:2,000; Research Diagnostics, Flanders, NJ) in 12% bovine serum albumin-PBS (v/v), visualized by secondary biotinylated goat anti-guinea pig/streptavidin-Texas red (diluted 1:100; Vector Labs, Burlingame, CA) or FITC-labeled anti-rabbit IgG (diluted 1:100; The Jackson Laboratory, Bar Harbor, ME) antibodies (28) (29) (30) (31) (32) (33) . For 5-bromo-4-deoxyuridine (BrdUrd) labeling, mice were injected i.p. with 125 mg/kg BrdUrd (Sigma, Dorset, United Kingdom) in sterile 0.9% salt solution 2 hours before biopsy. Deparaffinized sections were subjected to antigen retrieval (boiling for 10 minutes in 10 mmol/L sodium citrate buffer; Lab Vision, Fremont, CA) and immunofluorescence was done by overnight incubation with FITC-conjugated anti-BrdUrd (Becton Dickinson, Oxford, United Kingdom) counterstained with anti-K14. Mitotic index was determined by assaying the number of BrdUrd-labeled nuclei per millimeter of basement membrane (separate counts of three areas per section, three sections per tumor, and five tumors per genotype).
Western blot analysis. Primary transgenic keratinocytes isolated from newborn epidermis (34) 
Results
Phenotypes of RU486-treated compound genotypes. To study the effects of PTEN loss in ras Ha -mediated skin carcinogenesis yet limit PTEN ablation to RU486-treated cutaneous keratinocytes, K14.cre/D5PTEN mice were crossed with two lines of HK1.ras mice-line 1276, which exhibits an initiated skin without papillomas (28) , and line 1205, which exhibits regression-prone papillomas (31) . RU486-treated K14.cre/PTEN flx/flx cohorts, and, to a lesser extent, K14.cre/PTEN wt/flx , displayed a thickened skin, mild alopecia, and a prominent hyperkeratosis most noticeably on ears (100% mice, n = 58; Fig. 1A (Fig. 1E) instead of progression. Of the eventual 126 HK1.ras/K14.cre/PTEN flx/flx tumors analyzed from eventually 60 animals, only 6 (f5%) spontaneously progressed to squamous cell carcinoma (below). RU486-mediated exon 5 ablation was confirmed in vivo by the presence of a 400 bp truncated D5PTEN PTEN flx/flx allele and mRNA analyzed by RT-PCR to confirm HK1.ras expression (Fig. 1F) . To confirm PTEN protein loss and identify effects on target molecules, primary keratinocytes were analyzed for expression of total PTEN, phospho-AKT, and total AKT (Fig. 1G) . Total PTEN expression levels were lower as D5PTEN protein is unstable (14, 21) and loss of phosphatase activity resulted in elevated AKT phosphorylation, also observed in HK1.ras keratinocytes, and increased further in HK1.ras/K14.cre/ PTEN flx/flx keratinocytes. Histopathology of HK1-#5PTEN epidermis and tumors. Untreated K14.cre/PTEN Àwt/flx Àflx/flx epidermis appeared normal ( Fig. 2A) and untreated 1276 HK1.ras/K14.cre/PTEN Àwt/flx,Àflx/flx controls were identical to parental 1276, exhibiting mild keratinocyte hyperplasia, little hyperkeratosis, and a relative order to keratinocyte differentiation (Fig. 2B ). RU486-treated K14.cre/ PTEN flx/flx epidermis also gave hyperplasia but with a prominent, granular layer, a folded (papillomatous) appearance and moderate hyperkeratosis (Fig. 2C) . In treated HK1.ras/K14.cre/PTEN flx/flx cohorts, both hyperplasia and hyperkeratosis increased, giving rise to a characteristic acanthotic, highly tortuous papillomatous histotype (Fig. 2D) , with novel squamous cell cysts in the dermis (Fig. 2E) , which, alongside sebocyte clusters, probably derive from K14-driven, D5PTEN-mediated failed hair follicle differentiation, resulting in alopecia. Papilloma histology in untreated HK1.ras/ K14.cre/PTEN wt/flx was indistinguishable from typical HK1.ras papillomas (28) (29) (30) (31) , exhibiting an organized, well-differentiated nature, with little dysplasia, moderate dermal infiltrate, and few signs of progression (Fig. 2F ). RU486-treated HK1.ras/D5PTEN papillomas revealed a similar histotype but with a more dysplastic appearance and increased areas of keratin (Fig. 2G) . Eventually, occasional well-differentiated carcinomas appeared (Fig. 2H ), histologically indistinguishable from squamous cell carcinomas derived from TPA promotion (compare Fig. 2H with 3F); however, unlike TPA-promoted equivalents, spontaneous squamous cell carcinomas displayed an etiology (i.e., rare/latency >6 months) and flx/flx squamous cell carcinomas. G, Western blot analysis of PTEN and phospho-AKT or total AKT proteins in primary transgenic keratinocytes. RU486 treatment reduces PTEN expression, as the D5PTEN protein is unstable, resulting in an increase in activated phospho-AKT, which undergoes a further increase in HK1.ras/K14.cre/ PTEN flx/flx keratinocytes. Untreated HK1.ras/K14.cre/PTEN flx/flx keratinocytes also exhibited increased phospho-AKT, whereas total AKT levels remained elevated in the proliferative culture conditions regardless of genotype, also observed in vivo (Fig. 6 ). Cells were cultured with RU486 as indicated. differentiation marker profiles identical to all previous HK1.ras cooperation models (32, 33) . TPA promotion of HK1-#5PTEN transgenic mice. TPA promotion of untreated 1276 HK1.ras/PTEN wt/wt, wt/flx, flx/flx cohorts was identical to parental HK1.ras 1276 mice (31, 33) , giving increased epidermal hyperplasia but an ordered differentiation pattern to the expanded epidermal compartments (Fig. 3A) . At prepapilloma stages, TPA-promoted, RU486-treated K14.cre/ PTEN flx/flx cohorts exhibited increased hyperplasia dominated by hyperkeratosis (Fig. 3B) . Similarly, TPA promotion of RU486-treated HK1.ras/K14.cre/PTEN flx/flx cohorts increased epidermal hyperplasia and papillomatosis (Fig. 3C ), but at higher magnification ( Fig. 3D ) the appearance of multiple microcyst-like structures with a greater prominence of the granular layer suggests that the epidermis attempts to compensate for TPA-mediated proliferation following PTEN loss via accelerated differentiation clearly indicated on analysis of atypical differentiation marker expression ( TPA promotion of RU486-treated K14.cre/PTEN flx/flx cohorts resulted in novel papillomas in f70% of animals following long latency (16-20 weeks) . At 24 weeks, papillomas had not progressed to squamous cell carcinoma but did possess the D5PTEN-associated, highly keratotic histotype (Fig. 3E ) when compared with typical HK1.ras papillomas. Conversely, TPA promotion of HK1.ras/K14.cre/PTEN flx/flx cohorts exhibited papillomas that progressed to well-differentiated squamous cell carcinoma (Fig. 3F ) in most (90%) animals by 12 to 16 weeks, unless culled earlier due to tumor burden. However, there was little difference in histotype between spontaneous and TPAinduced squamous cell carcinomas (Fig. 2F versus 3G ) despite a major difference in keratin marker profiles between the two types of squamous cell carcinomas. As spontaneous ras Ha activation can be a conversion event (33, 34) and was observed in papillomatogenesis following chronic TPA promotion (35, 36) , tumors were analyzed for endogenous c-ras
Ha activation [via PCR and XbaI digestion (24) or direct sequencing] without success in TPA-promoted K14.cre/PTEN flx/flx papillomas (n = 6), spontaneous HK1.ras/K14.cre/PTEN flx/flx squamous cell carcinoma (n = 4), or TPA-induced squamous cell carcinomas (n = 8; not shown).
Analysis of mitotic activity in HK1.ras/#5PTEN epidermis and tumors. The mitotic index was determined via the numbers of Fig. S1F versus S1H) .
Following TPA promotion, normal skin hyperplasia gave a mitotic index (11.6 F 3.3) wt/flx tumor histology shows a well-organized squamous cell papilloma with an ordered nature to keratinocyte differentiation and no evidence of progression. G, RU486-treated 1205 HK1.ras/K14.cre/PTEN wt/flx littermate tumor reveals a similar squamous papilloma histotype with a dysplastic appearance accompanied by hyperkeratosis giving rise to small keratin pearls, but no evidence of carcinoma. H, spontaneous, well-differentiated squamous cell carcinoma histology, exhibited at low frequency in 1276 HK1.ras/K14.cre/ PTEN flx/flx cohorts, was indistinguishable from TPA-promoted equivalents. Magnification, Â50 (A-D, F , and G) and Â100 (E and H ). A, TPA promotion of 1276 HK1.ras epidermis gives increased hyperplasia, little hyperkeratosis, and an ordered differentiation pattern. B, at 16 weeks, TPA-promoted RU486-treated K14.cre/PTEN flx/flx skin displayed increased hyperplasia and an expanded spinous and granular layers (acanthosis), which gave a highly convoluted appearance dominated by a significant hyperkeratosis. C, TPA-promoted, RU486-treated HK1.ras/K14.cre/PTEN flx/flx skin displayed increased hyperplasia and changes to ordered keratinocyte differentiation, but failed hair follicle differentiation was demonstrated by increased sebocyte clusters rather than large dermal cysts. D, at higher magnification, this anomalous differentiation in TPA-promoted HK1.ras/K14.cre/PTEN flx/flx epidermis is typified by spinous and granular cells in the proliferative basal compartment, and appearance of novel microcysts/keratin pearls. E, eventually, TPA promotion of K14.cre/PTEN flx/flx gave novel squamous cell papillomas with a histotype similar to HK1.ras papillomas (Fig. 2F ) but with characteristic D5PTEN-associated keratosis. F, TPA promotion of HK1.ras/K14.cre/PTEN flx/flx cohorts rapidly elicited well-differentiated squamous cell carcinomas, indistinguishable from their spontaneous counterparts. Magnification, Â25 (B), Â50 (A, C , and E), and Â100 (D and H ). that K14.cre/PTEN flx/flx epidermis countered TPA-induced proliferation via increased hyperkeratosis (Fig. 3B) . As above, complete loss of PTEN in TPA-promoted HK1.ras/K14.cre/PTEN flx/flx papillomas doubled the index (98.1 F 11.9) to levels again approaching squamous cell carcinomas (108.1 + 14.2), although one additional striking facet was the level of labeling recorded in benign K14.cre/ PTEN flx/flx papillomas (69.9 F 8.3), reminiscent of HK1.p53 gainof-function papillomas (37) .
Expression of tumor progression marker keratins K1 and K13 in HK1.ras/#5PTEN carcinogenesis. In all previous HK1 conversion models (28) (29) (30) (31) (32) (33) , the gradual loss of keratin K1 expression, a marker of early terminal differentiation, and uniform appearance of keratin K13, a marker of simple internal epithelia, was indicative of progression to carcinoma associated with ras Ha activation as a transgene or via endogenous mutation (32, 33, 37) . Consistent with this progression profile, 100% of HK1.ras/K14.cre/ PTEN wt/wt, wt/flx flx/flx papillomas exhibited strong K1 expression that became reduced with increasing papilloma aggression (n = 26; Fig. 4A ) and lost on spontaneous conversion to squamous cell carcinomas (n = 6; Fig. 4B ). Conversely, TPA-promoted, RU486-treated K14.cre/PTEN flx/flx papillomas (n = 12) exhibited strong K1 expression (Fig. 4C ), which lacked a delay in onset of K1 expression, observed in HK1.ras-mediated papillomas, due to proliferative basal layer expansion ( Fig. 5; refs. 28-33). Moreover, TPA-promoted HK1.ras/K14.cre/PTEN flx/flx papillomas (taken early, n = 6) and carcinomas (n = 15) possessed this atypical retention of K1 expression (Fig. 4D) .
A novel keratin K13 expression profile was also observed. In spontaneous HK1.ras/K14.cre/PTEN flx/flx papillomas (Fig. 4E ) and initially in TPA-promoted K14.cre/PTEN flx/flx papillomas (Fig. 4F ), K13 was sporadically expressed, increasing in HK1.ras/K14.cre/ PTEN flx/flx papillomas to become uniform in (rare) spontaneous squamous cell carcinomas (Fig. 4G) . However, following TPA promotion, all HK1.ras/K14.cre/PTEN flx/flx carcinomas tested (n = 15) were completely devoid of K13 expression (Fig. 4H) . Moreover, during TPA-promoted K14.cre/PTEN flx/flx papillomatogenesis, the initial sporadic K13 expression pattern, exemplified in HK1.ras-mediated progression, became confined to ever-decreasing areas (Fig. 4F) , consistent with the overgrowth of K13-negative keratinocytes. Hence, this novel, unique K1/K13 expression profile would seem to be associated with a TPA/D5PTEN-mediated pathway of progression. Atypical expression of early-and late-stage differentiation markers in HK1.ras/#5PTEN epidermis and papillomas. To assess for changes in keratinocyte differentiation, immunofluorescence was done to analyze early-stage keratin K1 and late-stage loricrin and filaggrin expression (Fig. 5) . As cited above, expansion of the proliferative basal layer creates an apparent delay in onset of keratin K1 expression (28-33), a result observed in unpromoted HK1.ras/K14.cre/PTEN flx/flx hyperplasia (Fig. 5A) . However, this hallmark of keratinocyte hyperproliferation was absent in TPApromoted HK1.ras/K14.cre/PTEN flx/flx epidermis (Fig. 5B ) despite high proliferation rates and suprabasal BrdUrd labeling (see Supplementary Data). This subtle effect was associated with TPA promotion, as unlike TPA-promoted K14.cre/PTEN flx/flx counterparts (Fig. 4C) , spontaneous HK1.ras/K14.cre/PTEN flx/flx papillomas retained the typical delay in onset of K1 expression (Fig. 5C) .
Atypical, early loricrin ( Fig. 5D-F) and filaggrin ( Fig. 5G-I ) expression was also observed in TPA-treated epidermis following PTEN loss. Hyperplastic HK1.ras epidermis exhibits loricrin (Fig. 5D) and filaggrin (Fig. 5G ) expression restricted to the granular layers. However, following TPA/RU486 treatment, HK1.ras/K14.cre/PTEN flx/flx epidermis exhibits a diffuse, strong loricrin expression in cells of the spinous and basal compartments (Fig. 5E ), whereas filaggrin expression was observed from the spinous layer upward (Fig. 5H ) and both were expressed at microcyst sites ( Fig. 5E and H) . In addition, instead of the usual reduction in expression during HK1.ras-mediated tumor progression (31-33), HK1.ras/K14.cre/PTEN flx/flx papillomas retained loricrin (Fig. 5F) and filaggrin (Fig. 5I) at sites of high mitotic activity (e.g., Fig. 5F versus Supplementary Fig. S1F ). This expression profile was also observed in TPA-promoted K14.cre/ PTEN flx/flx papillomas; however, in carcinomas, loricrin and filaggrin expression were lost (not shown).
Analysis of activated AKT, MAPK signaling, and cyclin expression. Given the atypical K1 and K13 expression data, the relative contributions of ras Ha or PTEN signaling were determined in tumor progression (Fig. 6) . Total AKT and activated phospho-AKT, major targets for PTEN regulation (1-3, 9), were initially analyzed in vitro to confirm functional PTEN exon 5 loss (Fig. 1G) . In vivo, RU486 treatment increased total AKT protein in all hyperplastic epidermis and tumors regardless of histotype, etiology, or genotype ( lane 1 versus lanes 2-13) . Following the sequential loss of each functional PTEN allele, an increase in phospho-AKT expression was observed, increased further by TPA promotion (lanes 2-4) . HK1.ras expression also gave a small rise in phospho-AKT levels (lane 5 versus lane 1), whereas HK1.ras/D5PTEN synergism in severely hyperplastic epidermis (lane 6) gave high phospho-AKT levels, similar to that of TPA-promoted K14.cre/PTEN flx/flx skin (lane 4). In overt tumors, HK1.ras papillomas exhibited slightly elevated phospho-AKT levels (lane 7), whereas HK1.ras/D5PTEN cooperation increased levels further in both heterozygous (lane 8) and homozygous papillomas (lanes 9 and 10). However, the highest levels of activated phospho-AKT expression were observed in TPApromoted carcinomas (lanes 11-13) .
MAPK signaling, a target of both positive ras (8) and negative PTEN regulation (9) , was determined by analysis of total and activated phospho-ERK 1 and 2. Oddly, given an obvious increased proliferation, total ERK 1 and 2 protein expression in hyperplastic K14.cre/PTEN wt/flx and K14.cre/PTEN flx/flx was lower than normal epidermis (lanes 1-3) , becoming elevated following TPA promotion. Conversely, HK1.ras expression induced high levels of total ERK proteins in hyperplastic epidermis and papillomas (lanes 5-8), regardless of PTEN status, until late-stage papillomas (lanes 9 and 10), where PTEN loss significantly down-regulated expression of total ERK proteins, which then remained surprisingly low in TPA-promoted squamous cell carcinomas (lanes 11-13) . Activated phospho-ERK expression presented a more complex picture. In preneoplastic K14.cre/PTEN flx/flx hyperplasia, phospho-ERK levels were elevated (lane 3) despite the down-regulation of total ERK proteins and TPA promotion increased this activity further (lane 4), consistent with elevation of total ERK proteins. As expected, high levels of phospho-ERK were detected in HK1.ras hyperplasia hyperplasia and despite high total ERK protein levels, phospho-ERK levels were then down-regulated (lane 6). Similarly, in HK1.ras papillomas, elevated phospho-ERK levels (lane 7) were sequentially lowered in HK1.ras/K14.cre/PTEN wt/flx papillomas (lane 8) becoming virtually undetectable in HK1.ras/K14.cre/PTEN flx/flx papillomas (lanes 9 and 10). However, phospho-ERK levels became elevated again in squamous cell carcinomas following TPA promotion.
The increased mitotic activity in all D5PTEN homozygotes (Table 2 ; Supplementary Data) prompted assessment of cell cycle deregulation via analysis of cyclin E2 (15) (16) (17) and cyclin D1 (8, 10, 16) . Epidermal expression of cyclin E2 increased following sequential PTEN loss and gave high levels in TPA-promoted K14.cre/PTEN flx/flx epidermis (lanes 2-4) . HK1.ras-induced hyperplasia gave only slightly elevated levels of cyclin E2 (lane 5 versus lane 1) and in hyperplastic HK1.ras/K14.cre/PTEN flx/flx epidermis, cyclin E2 expression increased to levels similar to, rather than above, the levels observed in K14.cre/PTEN flx/flx hyperplasia (lane 6 versus lane 3) and lower than TPA-treated K14.cre/PTEN flx/flx skin (lane 6 versus lane 4). That cyclin E2 levels were associated with D5PTEN expression was consistent with the small increase in cyclin E2 expression observed in HK1.ras papillomas (lane 7) compared with high cyclin E2 levels in HK1.ras/D5PTEN papillomas (lanes 8-10) , which became significantly increased in TPA-treated squamous cell carcinomas (lanes 11-13) .
Analysis of cyclin D1 expression gave similar elevated results but with a synergism between HK1.ras-and D5PTEN-induced deregulation in early papillomatogenesis. In D5PTEN-induced hyperplasia, cyclin D1 increased over normal (lanes 1-3) , with a further increase following TPA promotion (lanes 4). Hyperplastic HK1.ras epidermis also expressed elevated cyclin D1, which further increased in HK1.ras/K14.cre/PTEN flx/flx hyperplasia (lanes 5 and 6). Heterozygous HK1.ras/D5PTEN papillomas consistently expressed high levels compared with HK1.ras alone (lanes 7 and 8) , approaching that observed in TPA-promoted squamous cell carcinomas (lanes 11-13) . However, although still elevated, HK1.ras/K14.cre/PTEN flx/flx papillomas exhibited a decrease in cyclin D1 expression (lanes 9 and 10). Given the ERK data, it is tempting to speculate that this decrease in cyclin D1 reflects the change in relative contributions provided by HK1.ras versus PTEN loss in progression and that TPA interactions with D5PTEN (observed in lane 4) mediate the return to high levels in squamous cell carcinomas.
Discussion
This transgenic model of inducible PTEN loss and ras Ha activation identified an early synergism in papillomatogenesis Figure 5 . Atypical expression of early-and late-stage differentiation markers in HK1.ras/D5PTEN epidermis. A, hyperplastic HK1.ras (shown) or unpromoted HK1.ras/ K14.cre/PTEN flx/flx epidermis exhibit a delay in expression of keratin K1 (green ) due to expansion of the proliferative basal layer (counterstained in red for K14 ). B, TPA-promoted HK1.ras/K14.cre/PTEN flx/flx epidermis does not exhibit delayed K1 expression; rather, K1 staining remains immediately suprabasal as seen in normal epidermis. C, conversely, spontaneous HK1.ras/K14.cre/PTEN flx/flx papillomas display a delayed onset in K1 expression (compare with TPA-promoted K14.cre/ PTEN flx/flx papillomas; Fig. 4C ). D, loricrin expression (green ) in hyperplastic HK1.ras epidermis remains restricted to the expanded granular layer. E, in TPA-promoted HK1.ras/K14.cre/PTEN flx/flx epidermis, novel diffuse loricrin expression appears in cells of the spinous and basal compartments, with maximum expression surrounding the keratin pearls. F, in TPA-promoted HK1.ras/K14.cre/PTEN flx/flx papillomas, instead of the usual reduction, strong loricrin expression was retained and observed at sites of intense BrdUrd labeling (Supplementary Fig. S1F ). An identical series of results were obtained for filaggrin expression in hyperplastic HK1.ras epidermis (G ); TPA-promoted HK1.ras/K14.cre/PTEN flx/flx epidermis, although here filaggrin expression was confined to suprabasal layers (H); and TPA-promoted HK1.ras/K14.cre/PTEN flx/flx papillomas (I ).
and highlighted important roles for PTEN in maintenance of cutaneous homeostasis, as its loss induced an apparent compensatory keratinocyte differentiation program. Initially, RU486-treated K14.cre/PTEN flx/flx cohorts did not exhibit spontaneous tumors despite sustained long-term keratinocyte hyperplasia, but exhibited increased epidermal hyperkeratosis consistent with Cowden disease (6) . This was in sharp contrast to conditional K5.cre/ PTENfloxed mice where papillomas appeared by 3 to 4 months and were converted to carcinoma (23) . Logically, these differences center on the inducible versus conditional approach and, as PTEN loss compromises, e.g., p53 guardian functions (1-3, 11, 14) , reflect the number (hyperplasia) and type (stem cells/embryonic epidermis) of target keratinocytes susceptible to additional mutations. Unlike K14.cre/PTEN flx/flx cohorts, effects of PTEN loss in K5.cre/ PTENfloxed mice would begin immediately on development of the embryonic epidermis (E 13/14; ref. 38 ) and continue throughout development on a global rather than localized scale (23) . Moreover, K5.cre/PTENfloxed epidermis exhibited precocious hair follicle development during embryogenesis (23) , similar to that reported for h-catenin transgenics (39, 40) . This identified links between PTEN loss and E-cadherin/h-cat/wnt/Lef1 signaling (39-41) that effectively increased the numbers of PTEN-null bulge region stem cells at risk for additional mutations (27) , hence a predisposition to carcinogenesis. Conversely, RU486-treated K14.cre/PTEN flx/flx cohorts exhibited alopecia, as RU486-treated adult follicles formed cyst-like structures similar to Lef 1 mutants that interdict h-catenin signaling (42) , which would decrease stem cell targets. Nonetheless, given K14 promoter-targeting specificity elicits the same D5PTEN/p53 mutation susceptibility (14) in long-term keratinocyte hyperplasia (6-10 months), the lack of K14.cre/ PTEN flx/flx papillomas remained unclear. Clues to this lack of tumors came from analysis of keratinocyte differentiation, which highlighted complex mechanisms sensitive to PTEN loss that countered excess proliferation via the induction of a terminal differentiation program. For instance, following TPA promotion in D5PTEN epidermis, the increase in mitotic index, elevation of ERK signaling, AKT activity, and cyclins D1 and E2, was actively countered by a massive degree of hyperkeratosis, hence the latency period in appearance of TPA-promoted K14.cre/ PTEN flx/flx papillomas compared with HK1.ras (28, 31) . Analysis of keratin K1, an early marker of keratinocyte differentiation together with late-stage markers filaggrin and loricrin in TPApromoted HK1.ras/D5PTEN epidermis, revealed an early anomalous expression amidst a confusion of granular, spinous, and proliferative suprabasal cells together with epidermal microcysts. Indeed, when this putative protective mechanism was overcome in TPA-promoted K14.cre/PTEN flx/flx or HK1.ras K14.cre/PTEN flx/flx papillomas, this differentiation was echoed by lack of a delay in keratin K1 expression and retention, not loss, of loricrin and filaggrin. Given that TPA induces c-fos (43), it is noteworthy that this novel differentiation mechanism was observed in experiments exploring D5PTEN synergism with fos activation. 3 To maintain cutaneous homeostasis, such a sentinel differentiation program probably evolved to accommodate environmental mutations and yet prevent disruption of the paramount epidermal role in barrier maintenance. Given the links between PTEN and cell-to-cell adhesion signaling (12, 18, (39) (40) (41) , together with precocious follicle development (23) , this epidermal sensitivity to D5PTEN may reflect PTEN functions that recruit the necessary molecular scaffold for E-cadherin/h-catenin in maintenance of adherens junctions (44, 45) . Failure of E-cadherin-mediated adhesion resulted in a lethal neonatal phenotype of barrier dysfunction (46) ; thus, if PTEN was critical for E-cadherin function(s), then a default terminal differentiation program would be a logical mechanism to deploy following PTEN loss to counter proliferation and the dangers of a compromised epidermal barrier. Testing of these intriguing ideas await transgenic models of inducible E-cadherin and h-catenin knockout.
In papillomatogenesis, inducible D5PTEN expression provided a lesion-eliciting event for 1276 HK1.ras mice and accelerated papilloma appearance in promotion-sensitive HK1.ras 1205 mice, Figure 6 . Western analysis of AKT, MAPK, and cyclin signaling expression in HK1.ras/D5PTEN carcinogenesis. Tissues representative of each genotype and histotype, together with normal (*) skin were all treated with RU486 or promoted with TPA as shown. Equal quantities of protein where probed with antibodies as shown specific for activated and total AKT, activated and total ERK 1 and 2, and cyclins E2 and D1, using h-actin expression as a comparative loading control. See text for detailed description.
suggesting a constitutive promotion role. Due to loss of D5PTEN phosphatase activity in HK1.ras/K14.cre/PTEN flx/flx epidermis and tumors, an early synergism involved dual increase in active phospho-AKT expression in vitro and in vivo. Although consistent with previous chemical carcinogenesis studies (10, 24) and resistance to UV-induced apoptosis in vitro (23) , this occurred without changes in total AKT protein levels (24) , as general keratinocyte hyperplasia (or tissue culture) gave a continuous, elevated expression. Interestingly, at these early preneoplastic stages, total ERK 1 and 2 protein expression in RU486-treated K14.cre/PTEN wt/flx and K14.cre/PTEN flx/flx hyperplasia was lower than normal epidermis, returning to elevated levels following TPA promotion or HK1.ras expression (Fig. 6, lanes 1-4) . Also, despite PTEN being a negative regulatory element to MAPK signaling via down-regulation of AKT (1-3), D5PTEN did not increase activated phospho-ERK levels to that of TPA promotion or HK1.ras expression. These data may reflect the increased differentiation associated with D5PTEN expression in a feedback loop of decreased MAPK signaling. Thus, overt papillomatogenesis may require ras Ha activation (or TPA promotion in K14.cre/PTEN flx/flx cohorts) to reactivate MAPK signaling and escape this in vivo counter to PTEN loss, whereas D5PTEN would inhibit the potential apoptotic response to ras Ha activation (47) via increased antiapoptotic AKT expression. Nonetheless, in progression, all late-stage HK1.ras/D5PTEN papillomas consistently exhibited reduced total and phospho-ERK expression (Fig. 6, lanes 8-10) , suggesting that once papillomas were established, HK1.ras signaling became less significant and the elevated phospho-ERK levels observed on conversion (lanes 11-13) was due to TPA-mediated synergism with D5PTEN (below).
One important mechanism underlying papillomatogenesis was cell cycle deregulation, typified by the strikingly high mitotic indices following D5PTEN homozygosity, consistent with down-regulation of p53 (11, 14) . One arm involved dual elevation of cyclin D1 by both D5PTEN and HK1.ras, which culminated in high cyclin D1 levels in heterozygous HK1.ras/K14.cre/PTEN wt/flx papillomas. Previous ras Ha -activated chemical carcinogenesis studies also linked increased AKT activity with elevated cyclin D1 (10, 15) and an early promotion role was supported by increased AKT/cyclin D1 activity in preneoplastic TPA-promoted K14.cre/PTEN flx/flx epidermis or HK1.ras/K14.cre/PTEN flx/flx hyperplasia (Fig. 6) . However, as with reduced ERK expression, in HK1.ras/K14.cre/PTEN flx/flx papillomas, cyclin D1 levels were lower, possibly reflecting a reduced HK1.ras/ MAPK signaling contribution to this papilloma progression mechanism, subsequently restored to high levels by TPA promotion resulting in a high mitotic index with a propensity to conversion given the compromised p53 guardian functions (11, 14) . A second arm of cell cycle-mediated promotion involved failure of PTENmediated p27 kip regulation, which resulted in cyclin E2 overexpression (15) (16) (17) 22) . This promotion arm appeared independent of HK1.ras signaling, as elevation of cyclin E2 in hyperplastic K14.cre/PTEN wt/flx and K14.cre/PTEN flx/flx epidermis occurred in parallel to increased phospho-AKT levels but decreased ERK, whereas PTEN null-mediated cyclin E2 elevation gave a 50% increase in BrdUrd labeling regardless of HK1.ras expression. Furthermore, cyclin E2 levels remained relatively low in HK1.ras epidermis and papillomas and, in progression, cyclin E2 expression was maintained at high levels, unlike the transient decrease in cyclin D1 when phospho-ERK was reduced, becoming significantly increased on conversion to malignancy. Thus, one important mechanism underlying progression (or propensity for conversion) involved a PTEN/p27 kip /cyclin E2 pathway of failed cell cycle regulation and deregulated cyclin E2 expression maybe an important key as to why TPA-mediated progression seems to be accelerated via D5PTEN pathways (15) (16) (17) , consistent with reports that PTEN loss and p27 kip mutations induce progression in prostate carcinogenesis (17, 22) and are exploitable prognostic markers (48) .
With respect to tumor progression, these HK1 data assumed an intriguing aspect compared with earlier DMBA/TPA chemical carcinogenesis studies in conditional PTEN knockouts that achieved malignancy via mechanisms involving (presumably ras Ha activated; ref. 25 ) elevation of MAPK signaling (23) and increased AKT activity, whereas similar experiments using heterozygous knockouts found a distinct lack of MAPK activity and mutual exclusivity between PTEN loss and DMBA-induced ras Ha activation in carcinomas (24) . In HK1.ras/D5PTEN mice, two distinct pathways of progression arose. The first spontaneous conversion pathway was less aggressive, relatively rare (within this time frame), and expressed keratins K1 and K13 progression markers in an identical fashion to conversion mediated by HK1.ras or TPA-promoted endogenous c-ras Ha activation (refs. 31-33, 37 and references therein). The second, dependent on TPA promotion, was rapid, occurred at high frequency, and expressed K1 and K13 in a unique, novel fashion that may be a marker of this conversion pathway. Furthermore, this progression mechanism may involve a greater contribution of D5PTEN as opposed to HK1.ras. As outlined above in late-stage papillomas, both total and phospho-ERK, together with cyclin D1, were down-regulated although D5PTEN-associated AKT and cyclin E2 were consistently elevated. In addition, TPA promotion of K14.cre/PTEN flx/flx epidermis did not induce spontaneous c-ras
Ha activation, unlike all previous TPA-promoted HK1 transgenic or SENCAR carcinogenesis models (32) (33) (34) (35) (36) , which showed that D5PTEN can substitute for ras Ha activation in initiation, albeit as a much weaker initiator given the delay in onset of TPA-promoted K14.cre/PTEN flx/flx papillomas. Such TPA-promoted K14.cre/ PTEN flx/flx papillomas were not recorded within the time frame tested in K5.cre/PTENfloxed experiments, but Mao et al. (28) reported appearance of heterozygous PTEN knockout papillomas devoid of ras Ha mutations that arose via loss of the normal PTEN allele (29) . Moreover, in TPA-promoted K14.cre/PTEN flx/flx papillomas, following an initial expression of K13 in a typical HK1.rasassociated sporadic profile (Fig. 4E) , a subsequent decrease in keratin K13 was observed consistent with the gradual overgrowth of a separate population of papilloma cells (Fig. 4F) . Because TPAderived squamous cell carcinomas were characterized by this novel absence of K13, TPA-promoted K14.cre/PTEN flx/flx papillomas may represent an intermediate stage where a possibly ras Ha -independent TPA/D5PTEN mechanism begin to overlay the foundations of earlier HK1.ras/D5PTEN synergism and give rise to cells with increased malignant potential.
Hence, HK1.ras/D5PTEN data suggest that, in agreement with the heterozygous knockout study, although unable to conclude a mutual exclusivity between ras activation and D5PTEN (24), following initial synergism in early papillomatogenesis, TPA-mediated tumor progression seems to involve D5PTEN-associated pathways more so than HK1.ras, with a significant degree of cell cycle perturbation underlying progression due to cyclin E2 deregulation in particular. In the K5.cre/PTENfloxed study, the roles assigned to MAPK signaling may be due to in vitro analysis of ERK expression in epidermal growth factor-stimulated keratinocytes (23) versus tissues (this study; ref. 24) . Equally, this result may reflect the HK1.ras/D5PTEN spontaneous progression pathway, which is less aggressive in the inducible model as progression depends on acquired (unknown) mutations probably derived from PTEN/p53 guardian dysfunction (14) , which would be a more significant defect in TPA-promoted cohorts. Given that ras remains a promising target in the design of novel therapies (8) , these data may have important implications where PTEN is also compromised, as their action may eliminate a benign population following ras-dependent mechanisms with limited progression capability and select PTENnull-dependent keratinocytes with increased malignant potential.
